Eli Lilly (NYSE: LLY) has been on a winning streak recently, with shares popping up by roughly 60% since the start of 2024 ...

But Eli Lilly got there first. With the FDA's approval in early July of Kisunla, its new medicine for Alzheimer's developed ...

New AI software promises to make diagnosing dementia quicker and more accurate, helping doctors provide timely and effective ...

Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...

Prescribing information for the two anti-amyloid Alzheimer's drugs currently available in the U.S. -- lecanemab (Leqembi) and ...

We recently compiled a list of the 12 Best Dividend Stocks For Steady Growth. In this article, we are going to take a look at ...

Analyst Akash Tewari of Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), boosting the price target to ...

Boston University researchers developed an AI tool that accurately diagnoses 10 types of dementia, improving diagnosis ...

BU researchers created an algorithm capable of pinpointing causes of cognitive decline, using only patient information collected by physicians ...

Alzheimer’s drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (NHS) in Britain, ...

Shortly after a U.K. watchdog declined to endorse Biogen's ( NASDAQ: BIIB) Alzheimer's drug Leqembi for use in the country's ...

NeuroXT's state-of-the-art technology uses MRI data to understand the interaction between beta-amyloid and tau proteins—key players in Alzhemer's disease. This innovative approach has the potential to ...